Back to Agenda
New Approaches, Novel Endpoints, and Next-Generation Trials
Session Chair(s)
Jennifer Goldsack, MA, MBA, MS
Chief Executive Officer, Digital Medicine Society (DiMe), United States
Using a case study, we will illustrate CTTI recommended practices for selecting, developing, and including technology-derived endpoints in regulatory trials. Participants can apply best practices learned to other scenarios, including their own work.
Learning Objective : Describe approaches to identifying mobile technology-derived outcome measures that are most valuable and warrant development; Review approaches for optimizing the efficiency of technology-derived novel endpoint development; Discuss how to include and position technology-derived novel endpoints to be most impactful.
Speaker(s)
Jessie Bakker, PHD, MS
Vice President of Digital Measures and Diagnostics, Digital Medicine Society (DiMe), United States
Daniel Rollings Karlin, DrMed, MA, FAPA
Chief Medical Officer, MindMed, United States
Komathi Stem, MS
Chief Operating Officer, Glooko, United States
Have an account?